Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.55 |
| ▸ | ACP3 | P15309 | 3/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | MAN2A1 | Q16706 | 3/20 | 0.47 |
| ▸ | MAN1B1 | Q9UKM7 | 3/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | MAN2B1 | O00754 | 2/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4853220 | 1.00 | SMN1; SMN2 (0.61) | SMN1; SMN2ADRB2ACP3L3MBTL1ATM | |
| SCHEMBL424037 | 1.00 | SMN1; SMN2 (0.61) | SMN1; SMN2ADRB2ACP3L3MBTL1ATM | |
| SCHEMBL6472595 | 0.89 | ADRB2 (0.50) | SMN1; SMN2ADRB2ACP3L3MBTL1ATM | |
| SCHEMBL6514671 | 0.88 | ATM (0.66) | SMN1; SMN2ADRB2ACP3L3MBTL1ATM | |
| Hydrochloric Acid SCHEMBL6473470 | 0.88 | ADRB2 (0.52) | SMN1; SMN2ADRB2ACP3L3MBTL1ATM | |
| SCHEMBL323957 | 0.88 | ADRB2 (0.56) | SMN1; SMN2ADRB2ACP3L3MBTL1ATM | |
| SCHEMBL2602792 | 0.85 | SMN1; SMN2 (0.57) | SMN1; SMN2ADRB2ACP3L3MBTL1ATM | |
| SCHEMBL22445577 | 0.84 | TDP1 (0.58) | ADRB2L3MBTL1ALDH1A1MEN1KMT2A | |
| SCHEMBL12493466 | 0.84 | TDP1 (0.58) | ADRB2L3MBTL1ALDH1A1MEN1KMT2A | |
| SCHEMBL323594 | 0.82 | BCHE (0.55) | ATMEPHX2MAPTMEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160083391-A1 | TRICYCLIC PIPERAZINE DERIVATIVE | SUNOVION PHARMACEUTICALS INC (US) | 2016-03-24 | — | — | US | disclosed |
| CN-102186812-A | Methods for preparing fluoroalkyl arylsulfinyl compounds and fluorinated compounds thereto | UBE INDUSTRIES | 2011-09-14 | — | — | CN | disclosed |
| US-20110190511-A1 | Methods For Preparing Fluoroalkyl Arylsulfinyl Compounds And Fluorinated Compounds Thereto | IM&T RESEARCH, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| EP-2323974-A1 | METHODS FOR PREPARING FLUOROALKYL ARYLSULFINYL COMPOUNDS AND FLUORINATED COMPOUNDS THERETO | Ube Industries, Ltd. (JP) | 2011-05-25 | — | — | EP | disclosed |
| US-20100152463-A1 | Methods for Preparing Fluoroalkyl Arylsulfinyl Compounds and Fluorinated Compounds Thereto | IM&T RESEARCH, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| WO-2010022001-A1 | METHODS FOR PREPARING FLUOROALKYL ARYLSULFINYL COMPOUNDS AND FLUORINATED COMPOUNDS THERETO | IM&T RESEARCH, INC. (US) | 2010-02-25 | — | — | WO | disclosed |
| EP-1675851-B1 | METHOD FOR PRODUCING N-SUBSTITUTED 3BETA-AMINONORTROPANES | BOEHRINGER INGELHEIM INT (DE) | 2008-08-20 | — | — | EP | disclosed |
| US-7321042-B2 | Process for preparing N-substituted 3-β-aminonortropanes | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2008-01-22 | — | — | US | disclosed |
| EP-1778662-A1 | PHOTORACEMIZATION OF 2-TRIFLUOROMETHYL-2H-CHROMENE-3-CARBOXYLIC ACID DERIVATIVES | Warner-Lambert Company LLC (US) | 2007-05-02 | — | — | EP | disclosed |
| EP-1773802-A1 | ENANTIOSELECTIVE METHOD FOR SEPARING SUBSTITUTED 2-TRIFLUOROMETHYL-2H-CHROMENE-3-CARBOXYLIC ACID DERIVATIVES | Pharmacia & Upjohn Company LLC (US) | 2007-04-18 | — | — | EP | disclosed |
| US-20060020023-A1 | Racemization method | PHARMACIA & UPJOHN COMPANY LLC | 2006-01-26 | — | — | US | disclosed |
| US-20050096346-A1 | Process for preparing N-substituted 3-beta-aminonortropanes | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-05-05 | — | — | US | disclosed |
| EP-0405537-B1 | N-substituted cycloalkyl and polycycloalkyl alpha-substituted Trp-Phe- and phenethylamine derivatives | WARNER LAMBERT CO (US) | 2004-09-08 | — | — | EP | disclosed |
| US-5631281-A | COMPOUNDS FOR TREATMENT OF ANXIETY WITH INDOLE AMIDES | WARNER-LAMBERT COMPANY (US) | 1997-05-20 | — | — | US | disclosed |
| US-5622983-A | ANTIOBESITY AGENTS, ANTIPSYCHOTIC AGENTS, ANTIULCER AGENTS | WARNER-LAMBERT COMPANY (US) | 1997-04-22 | — | — | US | disclosed |
| US-5580896-A | Treatment of pain and colorectal cancer with dipeptoids of α-substituted Trp-Phe derivatives | WARNER-LAMBERT COMPANY (US) | 1996-12-03 | — | — | US | disclosed |
| US-5278316-A | Indoles | WARNER-LAMBERT COMPANY (US) | 1994-01-11 | — | — | US | disclosed |
| EP-0479910-A1 | N-SUBSTITUTED CYCLOALKYL AND POLYCYCLOALKYL ALPHA-SUBSTITUTED Trp-Phe- AND PHENETHYLAMINE DERIVATIVES | WARNER-LAMBERT COMPANY (US) | 1992-04-15 | — | — | EP | disclosed |
| WO-1991000274-A1 | N-SUBSTITUTED CYCLOALKYL AND POLYCYCLOALKYL ALPHA-SUBSTITUTED TRP-PHE- AND PHENETHYLAMINE DERIVATIVES | WARNER-LAMBERT COMPANY (US) | 1991-01-10 | — | — | WO | disclosed |
| EP-0405537-A1 | N-substituted cycloalkyl and polycycloalkyl alpha-substituted Trp-Phe- and phenethylamine derivatives | WARNER-LAMBERT COMPANY (US) | 1991-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096346-A1 | Process for preparing N-substituted 3-beta-aminonortropanes | ADRB1, ADRB3, ADRB2 | SMN1; SMN2 1720/4885ADRB2 3/4885ACP3 1191/4885 |
| US-20100152463-A1 | Methods for Preparing Fluoroalkyl Arylsulfinyl Compounds and Fluorinated Compounds Thereto | PFAS, AGPS, FDPS | SMN1; SMN2 4340/4885ADRB2 3691/4885ACP3 3530/4885 |
| US-20110190511-A1 | Methods For Preparing Fluoroalkyl Arylsulfinyl Compounds And Fluorinated Compounds Thereto | PFAS, AGPS, FDPS | SMN1; SMN2 2161/4885ADRB2 1920/4885ACP3 3657/4885 |
| US-20160083391-A1 | TRICYCLIC PIPERAZINE DERIVATIVE | PDE3A, PDE5A, PDE2A | SMN1; SMN2 3083/4885ADRB2 574/4885ACP3 69/4885 |
| US-20060020023-A1 | Racemization method | STS, SQLE, HAO2 | SMN1; SMN2 1179/4885ADRB2 143/4885ACP3 1828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.